1e
19
1
49
2
2
18
1b
1d
18
38
50
1d
2 29
1d
25
Gregory L. Beatty, MD, PhD
78
50
Professor of Medicine (Hematology-Oncology)
28
76
3
5f
Attending Physician, Hospital of the University of Pennsylvania
55
Director, Penn-Incyte Alliance
97
Director of Translational Research, University of Pennsylvania Pancreatic Cancer Research Center
80
Physician Lead for Pancreas Clinical Research, University of Pennsylvania
7a
co-Director of ACC T32 Training Program, University of Pennsylvania
11
Department: Medicine
4
1
23
1f
Graduate Group Affiliations
8
b
-
6b
- Cell and Molecular Biology 5c
- Immunology e
1d
46
Contact information
54
4
3
3
3
2
29
4
b
1f
54
Perelman Center for Advanced Medicine
20 South Pavilion, Rm 8-107
3e 3400 Civic Center Blvd
Philadelphia, PA 19104-5156
26
20 South Pavilion, Rm 8-107
3e 3400 Civic Center Blvd
Philadelphia, PA 19104-5156
35
ab
12
13
Education:
21 7 BS c
2c Bucknell University, 1995.
21 8 PhD c
33 University of Pennsylvania, 2000.
21 7 MD c
33 University of Pennsylvania, 2004.
c
3
3
3
3
8b
Permanent link21 7 BS c
2c Bucknell University, 1995.
21 8 PhD c
33 University of Pennsylvania, 2000.
21 7 MD c
33 University of Pennsylvania, 2004.
c
2 29
21
1e
1d
24
5e
8
1af Based on basic science discoveries, Dr. Beatty’s research is driving new clinical investigations emphasizing combinatorial immunotherapies to enhance therapeutic efficacy. His laboratory uses preclinical cancer models and advanced multiplex immunohistochemistry to deepen our understanding of immune regulation of tumors, supporting the development of next-generation immunotherapeutic strategies for clinical translation.
62
3a 1. Devora Delman, research specialist, lab manager
26 2. Yan Li, research specialist
2f 3. Kelly Markowitz, research specialist
4b 4. Heather Coho, research animal specialist, animal studies manager
28 5. Jack McVey, surgical resident
30 6. Anna Thickens, Ph.D. graduate student
33 7. Rebecca Yelton, Administrative Assistant
8
2e Past members of my laboratory include:
34 1. Santiago Lombo Luque, research specialist
24 2. Amy Shyu, masters student
2a 3. Kristen Schwab, medical student
30 4. Michael Chuang, undergraduate student
36 5. Patrick Guirnalda, post-doctoral researcher
3b 6. Whitney Gladney, Ph.D., post-doctoral researcher
34 7. Graham Tooker, post-baccalaureate student
3a 8. Kevin Alicea Torres, post-baccalaureate student
3b 9. Dawson Knoblock, Ph.D., post-doctoral researcher
2d 10. Irene Park, undergraduate student
39 11. Kristen Long, Ph.D., post-doctoral researcher
3d 12. Anusha Kalbasi, M.D., radiation oncology resident
31 13. Fee Bengsch, post-doctoral researcher
28 14. Evan Tooker, masters student
35 15. Chad Komar, undergraduate/masters student
32 16. Shabnam Eghbali, undergraduate student
2c 17. Robert Hu, undergraduate student
28 18. Rebecca Kim, medical student
2e 19. Jason Liu, combined degree student
2c 20. Jae Lee, combined degree student
48 21. Kathleen Graham, research specialist, animal studies manager
2b 22. Anni Liu, undergraduate student
34 23. Thomas Buckingham, undergraduate student
39 24. Meredith Stone, PhD, post-doctoral researcher
2a 25. Max Wattenberg, MD, Instructor
31 26. Stacy Thomas, MD/PhD graduate student
2b 27. Jesse Lee, PhD graduate student
30 28. Jackie Plesset, PhD graduate student
41 29. Veronica Herrera, research flow cytometry specialist
37 30. Renee, Chang, research histology specialist
35 31. Yuqing Xue, research histology specialist
32 32. Shaanti Choi-Bose, research specialist
2a 33. Hana Choi, research specialist
2c 35. Xiaoqing Pan, research specialist
65
8
20d Clinically, we analyze patient-derived samples to understand how macrophage and T cell biology influences metastatic disease and the efficacy of therapies. Preclinically, we use genetically engineered mouse models alongside advanced tissue imaging techniques, specifically multiplex immunohistochemistry, to study the dynamics of macrophages and T cells within the tumor microenvironment. This platform supports detailed mechanistic studies of immune interactions as well as rapid evaluation of novel immunotherapies.
8
23 Our research areas include:
8
6b 1. signaling pathways driving cross-talk between macrophages, T cells, and tumor cells in vivo,
78 2. contributions of hematopoietic and non-hematopoietic cells in shaping immune cell function within tumors,
67 3. trafficking and localization of macrophages and T cells to primary and metastatic sites,
68 4. strategies to harness both macrophages and T cells for effective anti-tumor immunity, and
59 5. impacts of chemotherapy and radiation on immune cell biology within tumors.
e 29
27
Description of Clinical Expertise
206 Dr. Beatty’s clinical expertise focuses on early-phase clinical trials for gastrointestinal malignancies, including pancreatic, esophageal, and colon cancers. He has led the first clinical study of CD40 immunotherapy for pancreatic cancer—an innovative treatment that activates immune pathways involving macrophages and T cells to promote tumor regressions. He has also led first-in-human trials of a novel indoleamine 2,3-dioxygenase inhibitor and adoptive T cell therapies for pancreatic cancer.8
1af Based on basic science discoveries, Dr. Beatty’s research is driving new clinical investigations emphasizing combinatorial immunotherapies to enhance therapeutic efficacy. His laboratory uses preclinical cancer models and advanced multiplex immunohistochemistry to deepen our understanding of immune regulation of tumors, supporting the development of next-generation immunotherapeutic strategies for clinical translation.
62
Description of Other Expertise
3a Current members of my laboratory include:3a 1. Devora Delman, research specialist, lab manager
26 2. Yan Li, research specialist
2f 3. Kelly Markowitz, research specialist
4b 4. Heather Coho, research animal specialist, animal studies manager
28 5. Jack McVey, surgical resident
30 6. Anna Thickens, Ph.D. graduate student
33 7. Rebecca Yelton, Administrative Assistant
8
2e Past members of my laboratory include:
34 1. Santiago Lombo Luque, research specialist
24 2. Amy Shyu, masters student
2a 3. Kristen Schwab, medical student
30 4. Michael Chuang, undergraduate student
36 5. Patrick Guirnalda, post-doctoral researcher
3b 6. Whitney Gladney, Ph.D., post-doctoral researcher
34 7. Graham Tooker, post-baccalaureate student
3a 8. Kevin Alicea Torres, post-baccalaureate student
3b 9. Dawson Knoblock, Ph.D., post-doctoral researcher
2d 10. Irene Park, undergraduate student
39 11. Kristen Long, Ph.D., post-doctoral researcher
3d 12. Anusha Kalbasi, M.D., radiation oncology resident
31 13. Fee Bengsch, post-doctoral researcher
28 14. Evan Tooker, masters student
35 15. Chad Komar, undergraduate/masters student
32 16. Shabnam Eghbali, undergraduate student
2c 17. Robert Hu, undergraduate student
28 18. Rebecca Kim, medical student
2e 19. Jason Liu, combined degree student
2c 20. Jae Lee, combined degree student
48 21. Kathleen Graham, research specialist, animal studies manager
2b 22. Anni Liu, undergraduate student
34 23. Thomas Buckingham, undergraduate student
39 24. Meredith Stone, PhD, post-doctoral researcher
2a 25. Max Wattenberg, MD, Instructor
31 26. Stacy Thomas, MD/PhD graduate student
2b 27. Jesse Lee, PhD graduate student
30 28. Jackie Plesset, PhD graduate student
41 29. Veronica Herrera, research flow cytometry specialist
37 30. Renee, Chang, research histology specialist
35 31. Yuqing Xue, research histology specialist
32 32. Shaanti Choi-Bose, research specialist
2a 33. Hana Choi, research specialist
2c 35. Xiaoqing Pan, research specialist
65
Description of Research Expertise
1d4 My laboratory integrates basic science and clinical research to investigate the role of innate and adaptive immunity—particularly monocytes, macrophages, and T cells—in regulating tumor biology in pancreatic and other gastrointestinal cancers. We also study malignancies like glioblastoma, which have shown limited success with immunotherapy. We hypothesize that these immune cells are key regulators of tumor progression and therapeutic outcomes.8
20d Clinically, we analyze patient-derived samples to understand how macrophage and T cell biology influences metastatic disease and the efficacy of therapies. Preclinically, we use genetically engineered mouse models alongside advanced tissue imaging techniques, specifically multiplex immunohistochemistry, to study the dynamics of macrophages and T cells within the tumor microenvironment. This platform supports detailed mechanistic studies of immune interactions as well as rapid evaluation of novel immunotherapies.
8
23 Our research areas include:
8
6b 1. signaling pathways driving cross-talk between macrophages, T cells, and tumor cells in vivo,
78 2. contributions of hematopoietic and non-hematopoietic cells in shaping immune cell function within tumors,
67 3. trafficking and localization of macrophages and T cells to primary and metastatic sites,
68 4. strategies to harness both macrophages and T cells for effective anti-tumor immunity, and
59 5. impacts of chemotherapy and radiation on immune cell biology within tumors.
e 29
23
1a4 Lee J.W., Stone M.L., Porrett P.M., Thomas S.K., Komar C.A., Li J.H., Delman D., Graham K., Gladney W.L., Hua X., Gao M., Liu D., Borad M.J., Ramanathan R.K., Carpenter E.L., Ji A., de Beer M.C., de Beer F.C., Webb N.R., and G.L. Beatty: Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature 567(7747): 249-252, Mar 2019.
193 Xu, J., Sai, H., Li, Y., Jordan, A.C., McGettigan, S.E., Chen, J-H., Bedoya, F., Fraietta, J.A., Gladney, W.L., Melenhorst, J.J., and G.L. Beatty: Peripheral blood T cell fitness is diminished in patients with pancreatic carcinoma but can be improved with homeostatic cytokines. Cell Mol Gastroenterol Hepatol 8(4): 656-658, 2019.
140 Liu M, O'Connor RS, Trefely S, Graham K, Snyder NW, Beatty GL.: Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated 'don't eat me signal' Nat Immunol 20(3): 265-275, Mar 2019.
1a0 Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, Gladney WL, Levine BL, Melenhorst JJ, Plesa G, June CH.: Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology 155(1): 29-32, Jul 2018.
143 Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA, Beatty GL.: IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma. Cancer Discov 6(4): 400-413, Apr 2016.
c4 Beatty GL, Gladney WL.: Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 21(4): 687, Feb 2015.
169 Beatty GL, Winograd R, Evans RA, Long KB, Luque SL, Lee JW, Clendenin C, Gladney WL, Knoblock DM, Guirnalda PD, Vonderheide RH.: Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. Gastroenterology 149(1): 201-10, Jul 2015.
19d Beatty, GL., Torigian, DA., Chiorean EG, Saboury B, Brothers, A., Alavi A. Troxel, AB, Sun W, Teitelbaum UR, Vonderheide RH, PJ O'Dwyer: A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 19(22): 6286-95, Nov 2015.
169 Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun WJ, Huhn RD, Song WR, Li DG, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH: CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans. Science 331(6024): 1612-1616, Mar 25 2011.
2c
7
1d
1f
Selected Publications
11e Andrew H Ko, Alexander C Jordan, Evan Tooker, Simon F Lacey, Renee B Chang, Yan Li, Alan P Venook, Margaret Tempero, Lloyd Damon, Lawrence Fong, Mark H O'Hara, Bruce L Levine, J Joseph Melenhorst, Gabriela Plesa, Carl H June, Gregory L Beatty a5 : Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer Molecular Therapy 2 2c 28(11): 2367, Nov 2020.1a4 Lee J.W., Stone M.L., Porrett P.M., Thomas S.K., Komar C.A., Li J.H., Delman D., Graham K., Gladney W.L., Hua X., Gao M., Liu D., Borad M.J., Ramanathan R.K., Carpenter E.L., Ji A., de Beer M.C., de Beer F.C., Webb N.R., and G.L. Beatty: Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature 567(7747): 249-252, Mar 2019.
193 Xu, J., Sai, H., Li, Y., Jordan, A.C., McGettigan, S.E., Chen, J-H., Bedoya, F., Fraietta, J.A., Gladney, W.L., Melenhorst, J.J., and G.L. Beatty: Peripheral blood T cell fitness is diminished in patients with pancreatic carcinoma but can be improved with homeostatic cytokines. Cell Mol Gastroenterol Hepatol 8(4): 656-658, 2019.
140 Liu M, O'Connor RS, Trefely S, Graham K, Snyder NW, Beatty GL.: Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated 'don't eat me signal' Nat Immunol 20(3): 265-275, Mar 2019.
1a0 Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, Gladney WL, Levine BL, Melenhorst JJ, Plesa G, June CH.: Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology 155(1): 29-32, Jul 2018.
143 Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA, Beatty GL.: IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma. Cancer Discov 6(4): 400-413, Apr 2016.
c4 Beatty GL, Gladney WL.: Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 21(4): 687, Feb 2015.
169 Beatty GL, Winograd R, Evans RA, Long KB, Luque SL, Lee JW, Clendenin C, Gladney WL, Knoblock DM, Guirnalda PD, Vonderheide RH.: Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. Gastroenterology 149(1): 201-10, Jul 2015.
19d Beatty, GL., Torigian, DA., Chiorean EG, Saboury B, Brothers, A., Alavi A. Troxel, AB, Sun W, Teitelbaum UR, Vonderheide RH, PJ O'Dwyer: A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 19(22): 6286-95, Nov 2015.
169 Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun WJ, Huhn RD, Song WR, Li DG, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH: CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans. Science 331(6024): 1612-1616, Mar 25 2011.
2c